Regulus Therapeutics (RGLS) Stock Chart & Stock Price History $1.38 -0.02 (-1.43%) (As of 09:34 AM ET) Add Compare Share Share Chart Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Regulus Therapeutics Stock Price Performance 5 Day Performance-3.50%1 Month Performance-8.00%3 Month Performance-16.36%6 Month Performance-26.98%Year-To-Date Performance+7.81%1 Year Performance+0.73% Receive RGLS Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Regulus Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address JD Vance Predicts: Wall Street vs. Trump & Your Money (Ad)Trump's back in the White House, but Wall Street is pissed. Here's the deal: Wall Street's about to purposely crash the bond market to sabotage Trump's comeback.Get your free guide NOW before it's too late. RGLS Stock Chart for Thursday, November, 21, 2024 RGLS Chart by TradingView Regulus Therapeutics Stock Price History Daily Weekly Monthly Time Frame Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year Time Frame * Start Date * End Date Export to Excel DateOpening PriceClosing PriceHighLowVolumeMarket Capitalization11/20/2024$1.42$1.40-1.41%$1.44$1.39151,483 shs$91.70 million11/19/2024$1.42$1.42$1.44$1.36342,847 shs$93.01 million11/18/2024$1.43$1.42-0.70%$1.47$1.38297,513 shs$93.01 million11/15/2024$1.50$1.43-4.67%$1.52$1.40261,478 shs$93.67 million11/14/2024$1.50$1.50$1.55$1.49159,886 shs$98.25 million11/13/2024$1.56$1.50-3.85%$1.62$1.50246,646 shs$98.25 million Get the Latest News and Ratings for RGLS and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Regulus Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 11/12/2024$1.41$1.56+10.64%$1.65$1.40847,457 shs$102.13 million11/11/2024$1.47$1.41-4.08%$1.49$1.38501,512 shs$92.31 million11/08/2024$1.48$1.47-0.68%$1.50$1.44290,272 shs$96.24 million11/07/2024$1.51$1.48-1.99%$1.55$1.47640,659 shs$96.90 million11/06/2024$1.49$1.51+1.34%$1.56$1.46586,063 shs$98.86 million11/05/2024$1.49$1.49$1.52$1.46366,645 shs$97.55 million11/04/2024$1.49$1.49$1.55$1.46294,963 shs$97.54 million11/01/2024$1.46$1.49+2.05%$1.52$1.46321,305 shs$97.55 million10/31/2024$1.56$1.46-6.41%$1.59$1.46424,483 shs$95.58 million10/30/2024$1.61$1.56-3.11%$1.68$1.54820,365 shs$102.13 million10/29/2024$1.50$1.61+7.33%$1.68$1.451.41 million shs$105.41 million10/28/2024$1.44$1.50+4.17%$1.64$1.451.28 million shs$98.21 million10/25/2024$1.43$1.44+0.70%$1.51$1.39462,709 shs$94.28 million10/24/2024$1.46$1.43-2.05%$1.50$1.41134,618 shs$93.62 million10/23/2024$1.49$1.46-2.01%$1.49$1.39241,048 shs$95.58 million10/22/2024$1.50$1.49-0.67%$1.54$1.44178,441 shs$97.55 million10/21/2024$1.57$1.50-4.46%$1.65$1.49574,079 shs$98.20 million Related Companies Codexis Stock Price Chart XOMA Stock Price Chart Vanda Pharmaceuticals Stock Price Chart Lexicon Pharmaceuticals Stock Price Chart Verastem Stock Price Chart Achieve Life Sciences Stock Price Chart Agenus Stock Price Chart Fortress Biotech Stock Price Chart SAB Biotherapeutics Stock Price Chart Curis Stock Price Chart Receive RGLS Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Regulus Therapeutics and its competitors with MarketBeat's FREE daily newsletter. This page (NASDAQ:RGLS) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Regulus Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Regulus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
